Additionally, the NEAT1_1/miR-338-3p/AKR1C1 pathway is implicated in gefitinib resistance in EGFR-mutated lung adenocarcinoma, where increased AKR1C1 expression enhances defense against ferroptosis. Here, AKR1C1 is linked to lung adenocarcinoma.